EPISODE · Aug 12, 2025 · 12 MIN
Aptevo Therapeutics: Inside a Top-Tier Oncology Pipeline with COO Jeff Lamothe
from Small Stocks, Big Money · host RedChip Companies
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies through its proprietary bispecific antibody platforms, ADAPTIR® and ADAPTIR-FLEX®. The company is advancing a diverse pipeline that includes both clinical and preclinical candidates designed to harness the immune system to target hematologic and solid tumors with greater precision and safety. With a focus on innovation, Aptevo is leveraging modular antibody engineering to address areas of high unmet medical need and capture opportunities across multi-billion-dollar oncology markets.Aptevo Therapeutics is a client of RedChip. Visit APVOinfo.com to learn more.
What this episode covers
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies through its proprietary bispecific antibody platforms, ADAPTIR® and ADAPTIR-FLEX®. The company is advancing a diverse pipeline that includes both clinical and preclinical candidates designed to harness the immune system to target hematologic and solid tumors with greater precision and safety. With a focus on innovation, Aptevo is leveraging modular antibody engineering to address areas of high unmet medical need and capture opportunities across multi-billion-dollar oncology markets.Aptevo Therapeutics is a client of RedChip. Visit APVOinfo.com to learn more.
NOW PLAYING
Aptevo Therapeutics: Inside a Top-Tier Oncology Pipeline with COO Jeff Lamothe
No transcript for this episode yet
Similar Episodes
Apr 29, 2025 ·12m
Apr 27, 2025 ·11m
Apr 24, 2025 ·11m
Apr 22, 2025 ·14m
Apr 22, 2025 ·32m
Feb 27, 2025 ·0m